Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Xtandi
(United States) [Available]Synonyms :
Class :
Antineoplastic agents & Antiandrogens
Brand Name :
Xtandi
(United States) [Available]Synonyms :
Class :
Antineoplastic agents & Antiandrogens
Dosage forms & StrengthsÂ
Capsule, Oral:Â Â
40 mg Â
Tablet, Oral:Â
40 mgÂ
80 mg Â
Note: Patients under enzalutamide therapy should also be accompanied by a gonadotropin-releasing hormone analog concurrently Â
Metastatic:
160
mg
orally
once a day
Dose Adjustments
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 Inducers
may decrease the diagnostic effect when combined with Piflufolastat F18
the activity of norethisterone is reduced by administration of enzalutamide
by affecting intestinal metabolism, the effect of enzalutamide may be increased
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of abemaciclib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of abiraterone acetate
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of abrocitinib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of acalabrutinib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alfacalcidol
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alfentanil
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alpelisib
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alprazolam
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of amiodarone
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of amlodipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of apixaban
CYP3A strong enhancers of the small intestine may reduce the bioavailability of apremilast
CYP3A strong enhancers of the small intestine may reduce the bioavailability of aprepitant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of aripiprazole
CYP3A enhancers may decrease plasma concentrations of the active metabolite(s) of aripiprazole lauroxil
CYP3A enhancers reduces plasma concentrations of the active metabolite(s) of artemether
CYP3A strong enhancers of the small intestine may reduce the bioavailability of asunaprevir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of atazanavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of atogepant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of atorvastatin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of avacopan
CYP3A strong enhancers of the small intestine may reduce the bioavailability of avanafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of avapritinib
enzalutamide may reduce the therapeutic efficacy of avatrombopag
CYP3A strong enhancers of the small intestine may reduce the bioavailability of axitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of barnidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bedaquiline
CYP3A strong enhancers of the small intestine may reduce the bioavailability of belumosudil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of benidipine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of benperidol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of benzhydrocodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of betamethasone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bictegravir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bisoprolol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of blonanserin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bortezomib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bosutinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of brentuximab vedotin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of brexpiprazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of brigatinib
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of brivaracetam 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bromocriptine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bromperidol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of buprenorphine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of buspirone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of butorphanol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cabazitaxel
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cabozantinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of calcifediol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of calcitriol (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cannabidiol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cannabis
CYP3A strong enhancers of the small intestine may reduce the bioavailability of capmatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cariprazine
CYP2C19 enhancers may minimize the therapeutic activity of carisoprodol 
CYP2C9 enhancers may decrease the the bioavailability of celecoxib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of chlorpropamide enzal
antiandrogens may diminish the therapeutic effect of choline c 11 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cilnidipine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of citalopram
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clarithromycin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clindamycin (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clonazepam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clozapine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cobicistat 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cobimetinib
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of codeine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of copanlisib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of crizotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cyclosporine (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cyproterone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of daclatasvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dapsone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of daridorexant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of darunavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dasabuvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dasatinib
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of deflazacort
CYP3A strong enhancers of the small intestine may reduce the bioavailability of delamanid
CYP3A strong enhancers of the small intestine may reduce the bioavailability of delavirdine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dexamethasone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of diazepam
CYP2C9 enhancers may decrease the the bioavailability of diclofenac (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of diltiazem 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of disopyramide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of domperidone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of doravirine
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of doxercalciferol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of doxorubicin (conventional)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dronabinol 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dronedarone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of duvelisib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dydrogesterone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ebastine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of efavirenz
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elagolix
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elbasvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elexacaftor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eliglustat 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elvitegravir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of encorafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of enfortumab vedotin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of entrectinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eplerenone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eravacycline 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of erdafitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of erlotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of escitalopram 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of estazolam 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of eszopiclone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ethosuximide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etizolam
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etoposide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etoposide phosphate
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etoricoxib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of etravirine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of everolimus
CYP3A strong enhancers of the small intestine may reduce the bioavailability of evogliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of exemestane
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fedratinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of felbamate
CYP3A strong enhancers of the small intestine may reduce the bioavailability of felodipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fenfluramine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fentanyl 
CYP3A enhancers may enhance plasma concentrations of the active metabolite(s) of fexinidazoleenzal
CYP3A strong enhancers of the small intestine may reduce the bioavailability of finerenone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of flibanserin 
CYP2C9 enhancers may decrease the the bioavailability of fluvastatin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of fosaprepitant
phenytoin: enzalutamide may decrease the therapeutic efficacy of fosphenytoin-phenytoin
CYP3A enhancers (strong) may reduce the plasma concentrations of the active metabolite(s) of fostamatinib 
CYP3A enhancers (strong) may reduce the plasma concentrations of the active metabolite(s) of fostemsavir
antiandrogens may decrease the therapeutic effect of gallium ga 68 psma-11
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ganaxolone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of gefitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of gemigliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of gilteritinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of glasdegib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of glecaprevir and pibrentasvir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of guanfacine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of haloperidol
CYP3A strong enhancers of the small intestine may reduce the bioavailability of hormonal contraceptives
CYP3A strong enhancers of the small intestine may reduce the bioavailability of hydrocodone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of hydrocortisone (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ibrexafungerp  i
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ibrutinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of idelalisib
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of ifosfamide enzal
CYP3A strong enhancers of the small intestine may reduce the bioavailability of imatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of indinavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of infigratinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of irinotecan products
CYP3A strong enhancers may decrease the the bioavailability of isavuconazole  
CYP3A strong enhancers of the small intestine may reduce the bioavailability of isradipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of istradefylline
CYP3A strong enhancers of the small intestine may reduce the bioavailability of itraconazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivabradine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivacaftor 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivosidenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ixabepilone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ixazomib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ketamine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ketoconazole (systemic) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lacidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lapatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of larotrectinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lefamulin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lefamulin (intravenous)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lemborexant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lercanidipine
CYP2C9 enhancers may decrease the the bioavailability of lesinurad 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of leuprolide and norethindrone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of levamlodipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of levoketoconazole 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of levomethadone 
CYP3A enhancers (strong) may diminish the therapeutic effect of levonorgestrel (iud) CYP3A strong enhancers of the small intestine may reduce the bioavailability of levonorgestrel (iud) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lidocaine (systemic) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of linagliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lonafarnib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lopinavir
CYP3A enhancers (strong) may enhance the hepatotoxic effect of lorlatinib CYP3A strong enhancers of the small intestine may reduce the bioavailability of lorlatinib
CYP2C9 enhancers may decrease the the bioavailability of lornoxicam 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lumacaftor and ivacaftor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lumateperone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lurasidone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lurbinectedin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of macimorelin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of macitentan 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of manidipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of maraviroc
CYP3A strong enhancers of the small intestine may reduce the bioavailability of maribavir 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mavacamten 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mefloquine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of meperidine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methadone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methylergonovine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methylprednisolone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mianserin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of midazolam 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of midostaurin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mifepristone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mirabegron
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mirodenafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mirtazapine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mitapivat 
mobocertinib: CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of mobocertinib and may reduce the bioavailability of mobocertinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of naldemedine  enzal
CYP3A strong enhancers of the small intestine may reduce the bioavailability of naloxegol 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nateglinide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nelfinavir 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of neratinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of netupitant 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nevirapine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nicardipine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nifedipine management: avoid coadministration of nifedipine with strong CYP3A enhancers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nilotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nilvadipine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nimodipine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nintedanib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nirmatrelvir 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nisoldipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nitrendipine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of olaparib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of oliceridine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of olmutinib 
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of omeprazole 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ondansetron
CYP3A strong enhancers of the small intestine may reduce the bioavailability of osilodrostat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of osimertinib
enzalutamide may reduce the therapeutic efficacy of ospemifene 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of oxcarbazepine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of oxycodone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of paclitaxel (conventional) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of paclitaxel (protein bound) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pacritinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of palbociclib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of panobinostat 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pazopanib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pemigatinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of perampanel 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pexidartinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pimavanserin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of piperaquine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pitolisant 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of polatuzumab vedotin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ponatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pralsetinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of praziquantel 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of prednisolone (systemic) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of prednisone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of pretomanid 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of propafenone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of quetiapine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of quinidine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of quinine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of radotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ramelteon 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ranolazine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of reboxetine
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of regorafenib and it may reduce the bioavailability of regorafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of remdesivir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of repaglinide 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ribociclib
may reduce the therapeutic efficacy of enzalutamide
may reduce the therapeutic efficacy of enzalutamide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rilpivirine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rimegepant
CYP3A strong enhancers of the small intestine may reduce the bioavailability of riociguat
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ripretinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of risperidone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ritonavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rivaroxaban
CYP3A strong enhancers of the small intestine may reduce the bioavailability of roflumilast
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rolapitant 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of romidepsin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ruxolitinib (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of samidorphan 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of saquinavir management: consider alternatives to strong CYP3A enhancers in patients treated with saquinavir if combined, monitor closely for signs of decreased saquinavir concentrations and effects 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of saxagliptin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of selpercatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of selumetinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sertindole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sertraline
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sildenafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of simeprevir
enzalutamide may reduce the therapeutic efficacy of siponimod 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sirolimus (conventional)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sirolimus (protein bound)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of solifenacin 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sonidegib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sorafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sotorasib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of stiripentol 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sufentanil
CYP2C9 enhancers may decrease the the bioavailability of sulfonylureas 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sunitinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of suvorexant 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tacrolimus (systemic)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tadalafil
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tamoxifen 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tasimelteon 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tazemetostat 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of telithromycin
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of temsirolimus
CYP3A strong enhancers of the small intestine may reduce the bioavailability of teniposide
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tepotinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tetrahydrocannabinol  tetrahydrocannabinol and cannabidiol: CYP3A strong enhancers of the small intestine may reduce the bioavailability of tetrahydrocannabinol and cannabidiol  
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tezacaftor and ivacaftor
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of thiotepa and reduce the the bioavailability of thiotepa 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tiagabine
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of ticagrelor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tipranavir
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tivozanib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tofacitinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tolvaptan
CYP3A enhancers (strong) may decrease plasma concentrations of the active metabolite(s) of toremifene
CYP2C9 enhancers may decrease the the bioavailability of torsemide 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of trabectedin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tramadol 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of trazodone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of triamcinolone (systemic) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of triazolam 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tropisetron 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tucatinib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ubrogepant 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of udenafil 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ulipristal 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of upadacitinib 
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of vandetanib and reduce the the bioavailability 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of velpatasvir 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vemurafenib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of venetoclax 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of verapamil 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vilazodone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vincristine 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vincristine (liposomal) 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vinflunine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vinorelbine 
vitamin k antagonists (eg warfarin)
enzalutamide may reduce the therapeutic efficacy of vitamin k antagonists 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voclosporin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vonoprazan 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vorapaxar 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voriconazole
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vortioxetine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voxelotor
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voxilaprevir 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zaleplon 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zanubrutinib 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ziprasidone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zolpidem 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zonisamide 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zopiclone 
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zuclopenthixol
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib   
the effect of enzalutamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
enzalutamide decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
enzalutamide decreases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
enzalutamide decreases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
it decreases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
metronidazole/tetracycline/bismuth subsalicylateÂ
by altering the intestinal/hepatic CYP3A4 metabolism, the effects of enzalutamide will be decreased by tetracycline
It may diminish its effectiveness when combined with flotufolastat F-18
When enzalutamide is used together with oleandomycin, this leads to enhanced concentration serum of enzalutamide
When enzalutamide is used together with ridaforolimus, this leads to enhanced concentration serum of enzalutamide
the serum concentration of enzalutamide can be raised when it is combined with sulfanilamide
when both drugs are combined, there may be a reduced excretion rate of topotecan and result in a high level of serum concentration  
has an antagonistic effect over brentuximab vedotin, by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
may diminish the serum concentration
the serum levels of tocofersolan may be reduced with enzalutamide
The androgen signaling pathway is three times inhibited by the competitive androgen receptor (AR) inhibitor enzalutamide, which has negligible AR agonist action.Â
It prevents testosterone from attaching to its receptor, causing the receptor to move nuclear, and then interacting with chromosome DNA to activate oncogenes.Â
The affinity of enzalutamide for the AR is only 2-3 times lower than that of the natural ligand dihydrotestosterone, and 5 to 8 times higher than that of first-generation antiandrogens.Â
Frequency defined:Â
>10%:Â
Hypertension (14%)Â
Peripheral edema (15%)Â
Decreased appetiteÂ
HypermagnesemiaÂ
Weight loss (12%)Â
Decreased white blood cells Â
DiarrheaÂ
NauseaÂ
DizzinessÂ
FatigueÂ
HeadacheÂ
Muscle painÂ
DyspneaÂ
Back pain Â
1% to 10%Â
Cardiac arrhythmia (3%)Â
PruritisÂ
Bone fractureÂ
AnxietyÂ
Cognitive dysfunctionÂ
InsomniaÂ
Restless legÂ
HematuriaÂ
Muscle rigidity Â
<1%Â
Tongue edemaÂ
SeizureÂ
Facial edema Â
Frequency not defined:Â
Hypersensitivity reactionÂ
Â
NoneÂ
Contraindication:Â
NoneÂ
Caution:Â
SeizureÂ
Embryo-fetal toxicityÂ
DysphagiaÂ
Ischemic heart diseaseÂ
Falls and fracturesÂ
Pregnancy consideration: No data available regarding pregnancy effects of enzalutamide.Â
Lactation: excretion of enzalutamide in breast milk is unknown.Â
Pregnancy category:Â
A second-generation antiandrogen called enzalutamide inhibits the actions of androgen and the androgen receptor (AR) in prostate cancer. Â
Androgen deprivation therapy (ADT) is justified by the intimate relationship between AR activity and the development of prostate cancer, which is caused by the normal physiology of prostate cells.Â
Enzalutamide can inhibit cell development and trigger apoptosis, whereas other antiandrogens according to in vitro tests conducted on the human prostate cancer cell line VCaP.Â
The dose is administered with or without food through oral route.Â
To ensure that all the medication is successfully absorbed, patient should swallow the capsules or pills whole with enough water.Â
Avoid chewing, dissolving, or opening of capsules.Â
Tablets should not be cut, crushed, or chewed.Â
Generic Name: enzalutamideÂ
Why do we use enzalutamide?Â
Enzalutamide is indicated to treat non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence and a high risk of metastasis, as well as castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCSPC).Â
It is also used in combination with talazoparib to treat adult patients with mCRPC that has a mutation in the HRR gene.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
